MA46608B1 - Formulation liposomale utile pour le traitement du cancer - Google Patents
Formulation liposomale utile pour le traitement du cancerInfo
- Publication number
- MA46608B1 MA46608B1 MA46608A MA46608A MA46608B1 MA 46608 B1 MA46608 B1 MA 46608B1 MA 46608 A MA46608 A MA 46608A MA 46608 A MA46608 A MA 46608A MA 46608 B1 MA46608 B1 MA 46608B1
- Authority
- MA
- Morocco
- Prior art keywords
- compound
- cancer
- treatment
- liposomal formulation
- pyrimidin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- PKYIMGFMRFVOMB-UHFFFAOYSA-N 2-[5-[3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl]-6-(4-fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy-3-[2-[[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy]phenyl]propanoic acid Chemical compound ClC=1C(=C(C=CC=1OCCN1CCN(CC1)C)C1=C(SC=2N=CN=C(C=21)OC(C(=O)O)CC1=C(C=CC=C1)OCC1=NC(=NC=C1)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)F)C PKYIMGFMRFVOMB-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 235000020573 organic concentrate Nutrition 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
L'invention concerne une composition pharmaceutique liposomale comprenant de l'acide 2-{[5-{3-chloro-2-méthyl-4-[2-(4-méthylpipérazin-1-yl)éthoxy]phényl}-6-(4-fluorophényl)thiéno [2,3-d]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-méthoxyphényl)pyrimidin-4-yl]méthoxy}phényl) propanoïque, dénommé ici "composé a", ou un sel pharmaceutiquement acceptable de celui-ci. Plus spécifiquement, l'invention concerne un véhicule liposomal, une composition concentrée organique comprenant le composé a, et une composition pharmaceutique pour administration parentérale comprenant des liposomes et le composé a. En outre, l'invention concerne l'utilisation de telles compositions pour le traitement du cancer. Le 'composé a' tel qu'utilisé ici comprend tous les énantiomères, les diastéréoisomères, et les atropisomères de ceux-ci, ou des mélanges de ceux-ci, et également comprend éventuellement les sels pharmaceutiquement acceptables de ceux-ci.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306415 | 2016-10-28 | ||
| PCT/EP2017/077538 WO2018078064A1 (fr) | 2016-10-28 | 2017-10-27 | Formulation liposomale destinée à être utilisée dans le traitement du cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA46608A MA46608A (fr) | 2019-09-04 |
| MA46608B1 true MA46608B1 (fr) | 2022-08-31 |
Family
ID=57288337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46608A MA46608B1 (fr) | 2016-10-28 | 2017-10-27 | Formulation liposomale utile pour le traitement du cancer |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US10722466B2 (fr) |
| EP (1) | EP3532067B1 (fr) |
| JP (1) | JP7041676B2 (fr) |
| KR (1) | KR102653436B1 (fr) |
| CN (1) | CN109922808B (fr) |
| AR (1) | AR109981A1 (fr) |
| AU (1) | AU2017350499B2 (fr) |
| BR (1) | BR112019008263A2 (fr) |
| CA (1) | CA3041592C (fr) |
| CO (1) | CO2019004190A2 (fr) |
| CU (1) | CU20190046A7 (fr) |
| CY (1) | CY1125446T1 (fr) |
| DK (1) | DK3532067T3 (fr) |
| EA (1) | EA201991025A1 (fr) |
| ES (1) | ES2923929T3 (fr) |
| GE (1) | GEP20217244B (fr) |
| HR (1) | HRP20220952T1 (fr) |
| HU (1) | HUE059448T2 (fr) |
| IL (1) | IL266198B2 (fr) |
| LT (1) | LT3532067T (fr) |
| MA (1) | MA46608B1 (fr) |
| MD (1) | MD3532067T2 (fr) |
| MX (1) | MX391096B (fr) |
| MY (1) | MY194730A (fr) |
| PH (1) | PH12019500804A1 (fr) |
| PL (1) | PL3532067T3 (fr) |
| PT (1) | PT3532067T (fr) |
| RS (1) | RS63400B1 (fr) |
| RU (1) | RU2756755C2 (fr) |
| SG (1) | SG11201903326RA (fr) |
| SI (1) | SI3532067T1 (fr) |
| TN (1) | TN2019000117A1 (fr) |
| TW (1) | TWI749091B (fr) |
| UA (1) | UA126910C2 (fr) |
| UY (1) | UY37459A (fr) |
| WO (1) | WO2018078064A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202001182QA (en) | 2017-08-15 | 2020-03-30 | Abbvie Inc | Macrocyclic mcl-1 inhibitors and methods of use |
| CN110964034B (zh) * | 2018-09-29 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用 |
| AR116635A1 (es) * | 2018-10-15 | 2021-05-26 | Servier Lab | Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen |
| TWI849001B (zh) | 2018-11-14 | 2024-07-21 | 法商施維雅藥廠 | Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物 |
| TW202114682A (zh) | 2019-06-17 | 2021-04-16 | 法商施維雅藥廠 | Mcl-1抑制劑與乳癌標準療法之組合，其用途及醫藥組合物 |
| WO2022090443A1 (fr) | 2020-10-30 | 2022-05-05 | Les Laboratoires Servier | Administration et posologie pour une combinaison d'un inhibiteur de bcl-2 et d'un inhibiteur de mcl-1 |
| EP4312536A1 (fr) | 2021-04-01 | 2024-02-07 | Vestaron Corporation | Formulations de liposomes destinées à l'administration de pesticides et leurs procédés de production et d'utilisation |
| AU2022291381B2 (en) | 2021-06-11 | 2025-04-24 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| EP4351657A1 (fr) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Inhibiteurs de mcl-1 en combinaison avec des conjugués anti-corps-médicament |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS607932A (ja) * | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソーム懸濁液およびその製法 |
| GB8613811D0 (en) | 1986-06-06 | 1986-07-09 | Phares Pharm Res Nv | Composition & method |
| US5580899A (en) * | 1995-01-09 | 1996-12-03 | The Liposome Company, Inc. | Hydrophobic taxane derivatives |
| GB9601120D0 (en) | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
| WO2000000178A1 (fr) | 1998-06-30 | 2000-01-06 | Rohto Pharmaceutical Co., Ltd. | Compositions contenant des liposomes et/ou des emulsions et leur procede de preparation |
| DE60027730T2 (de) * | 1999-09-09 | 2007-03-29 | The Regents Of The University Of California, Oakland | Verabreichung von taxanen an angiogene blutgefässe mittels kationischer liposomen |
| KR20010100194A (ko) | 2000-03-13 | 2001-11-14 | 박호군 | 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법 |
| JP2002080400A (ja) | 2000-06-23 | 2002-03-19 | Takeda Chem Ind Ltd | リン脂質含有薬物の製造法 |
| CN1116875C (zh) | 2000-10-19 | 2003-08-06 | 南京振中生物工程有限公司 | 紫杉醇脂质组合物及其制备方法 |
| PT1389089E (pt) | 2001-03-27 | 2009-11-30 | Phares Pharm Res Nv | Processo e composição para solubilizar um composto biologicamente activo com uma baixa solubilidade em água |
| US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| WO2004069224A2 (fr) | 2003-02-03 | 2004-08-19 | Neopharm, Inc. | Taxane liposomal encapsule, stable, sterile et filtrable et autres medicament antineoplasiques |
| JP2005075783A (ja) | 2003-09-01 | 2005-03-24 | Otsuka Pharmaceut Factory Inc | 難溶性化合物の可溶化または分散化用組成物 |
| JP2005225818A (ja) | 2004-02-13 | 2005-08-25 | Otsuka Pharmaceut Factory Inc | パクリタキセル又はドセタキセルの医薬組成物 |
| CA2681302C (fr) | 2007-03-19 | 2013-07-23 | Dhiraj Khattar | Compositions proliposomales et liposimale de composes faiblement hydrosolubles |
| PL2344198T3 (pl) | 2008-09-27 | 2021-05-31 | Jina Pharmaceuticals Inc. | Preparaty farmaceutyczne na bazie lipidów do stosowania miejscowego |
| RU2476216C1 (ru) * | 2009-03-30 | 2013-02-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Липосомальная композиция |
| DK2508170T3 (en) | 2009-12-03 | 2015-09-21 | Jiangsu Hengrui Medicine Co | LIPOSOM OF IRINOTECAN OR ITS HYDROCHLORIDE AND ITS PROCEDURE |
| JP2012051823A (ja) | 2010-08-31 | 2012-03-15 | Fujifilm Corp | 難容性薬物含有水中油型乳化組成物及びその製造方法 |
| CN101926757B (zh) | 2010-09-01 | 2013-01-02 | 北京大学 | 一种难溶性药物的液体组合物及其制备方法 |
| CA2818018C (fr) | 2010-12-08 | 2016-02-02 | F. Hoffmann-La Roche Ag | Formulation liposomale de dalcetrapib |
| JP2014506922A (ja) | 2011-03-01 | 2014-03-20 | ティーオー − ビービービー ホールディング ベスローテン フェンノートシャップ | 難水溶性物質の高度なアクティブリポソームローディング |
| CN103622911B (zh) | 2013-11-19 | 2015-12-30 | 常州金远药业制造有限公司 | 一种难溶性药物脂质体制备方法 |
| FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2017
- 2017-10-27 BR BR112019008263A patent/BR112019008263A2/pt not_active Application Discontinuation
- 2017-10-27 CA CA3041592A patent/CA3041592C/fr active Active
- 2017-10-27 HR HRP20220952TT patent/HRP20220952T1/hr unknown
- 2017-10-27 KR KR1020197015033A patent/KR102653436B1/ko active Active
- 2017-10-27 UY UY0001037459A patent/UY37459A/es not_active Application Discontinuation
- 2017-10-27 WO PCT/EP2017/077538 patent/WO2018078064A1/fr not_active Ceased
- 2017-10-27 MA MA46608A patent/MA46608B1/fr unknown
- 2017-10-27 TN TNP/2019/000117A patent/TN2019000117A1/en unknown
- 2017-10-27 SI SI201731200T patent/SI3532067T1/sl unknown
- 2017-10-27 EP EP17787939.2A patent/EP3532067B1/fr active Active
- 2017-10-27 LT LTEPPCT/EP2017/077538T patent/LT3532067T/lt unknown
- 2017-10-27 MY MYPI2019002297A patent/MY194730A/en unknown
- 2017-10-27 MD MDE20190973T patent/MD3532067T2/ro unknown
- 2017-10-27 UA UAA201905614A patent/UA126910C2/uk unknown
- 2017-10-27 DK DK17787939.2T patent/DK3532067T3/da active
- 2017-10-27 US US16/344,431 patent/US10722466B2/en active Active
- 2017-10-27 CN CN201780067045.2A patent/CN109922808B/zh not_active Expired - Fee Related
- 2017-10-27 PT PT177879392T patent/PT3532067T/pt unknown
- 2017-10-27 TW TW106137030A patent/TWI749091B/zh not_active IP Right Cessation
- 2017-10-27 RU RU2019115688A patent/RU2756755C2/ru active
- 2017-10-27 EA EA201991025A patent/EA201991025A1/ru unknown
- 2017-10-27 JP JP2019522453A patent/JP7041676B2/ja not_active Expired - Fee Related
- 2017-10-27 PL PL17787939.2T patent/PL3532067T3/pl unknown
- 2017-10-27 GE GEAP201715047A patent/GEP20217244B/en unknown
- 2017-10-27 IL IL266198A patent/IL266198B2/en unknown
- 2017-10-27 AU AU2017350499A patent/AU2017350499B2/en not_active Ceased
- 2017-10-27 RS RS20220677A patent/RS63400B1/sr unknown
- 2017-10-27 ES ES17787939T patent/ES2923929T3/es active Active
- 2017-10-27 AR ARP170102984A patent/AR109981A1/es not_active Application Discontinuation
- 2017-10-27 CU CU2019000046A patent/CU20190046A7/es unknown
- 2017-10-27 SG SG11201903326RA patent/SG11201903326RA/en unknown
- 2017-10-27 MX MX2019004941A patent/MX391096B/es unknown
- 2017-10-27 HU HUE17787939A patent/HUE059448T2/hu unknown
-
2019
- 2019-04-12 PH PH12019500804A patent/PH12019500804A1/en unknown
- 2019-04-26 CO CONC2019/0004190A patent/CO2019004190A2/es unknown
-
2022
- 2022-08-02 CY CY20221100526T patent/CY1125446T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46608B1 (fr) | Formulation liposomale utile pour le traitement du cancer | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| WO2019246349A8 (fr) | Composés antagonistes du pcsk9 | |
| TN2016000227A1 (fr) | Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides. | |
| MA37405A1 (fr) | Composés hétérocyclyle | |
| MX2010003868A (es) | Cis-imidazolinas quirales. | |
| WO2019143902A3 (fr) | Hétérocycles substitués utiles en tant qu'agents antiviraux | |
| WO2017123884A8 (fr) | Composés hétérocycliques utilisés comme inhibiteurs du vrs | |
| MX347544B (es) | Antagonista de acido lisofostatidico 1 (lpa1) policiclico y usos del mismo. | |
| EA201690752A1 (ru) | Ингибиторы g12c kras | |
| EA201692095A1 (ru) | Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака | |
| MX2020001403A (es) | Nuevos derivados de quinolina. | |
| EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
| WO2006067614A3 (fr) | Derives heteroaromatiques utiles en tant qu'agents anticancereux | |
| EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
| TN2019000170A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| JP2015501833A5 (fr) | ||
| WO2014031438A3 (fr) | Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués | |
| MA38865A1 (fr) | Formulation comprenant un agent hypolipidémiant | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| EP4249071A3 (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
| AU2018272088A8 (en) | Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-N'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | |
| MA29278B1 (fr) | Composition pharmaceutique comprenant un derive de l'indolylmaleimide | |
| HK1255438A1 (zh) | 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 |